https://www.eurekalert.org/news-releases/939536
News Release 7-Jan-2022
Peer-Reviewed Publication
Institut Pasteur
-----
The scientists demonstrated that Omicron is much less sensitive to neutralizing antibodies than Delta. The scientists then analyzed the blood of people who had received two doses of the Pfizer or AstraZeneca vaccine. Five months after vaccination, the antibodies in the blood were no longer capable of neutralizing Omicron. This loss of efficacy was also observed in individuals who had been infected with SARS-CoV-2 within the past 12 months. Administering a booster dose of the Pfizer vaccine or a single vaccine dose in previously infected individuals led to a significant increase in antibody levels that was sufficient to neutralize Omicron. Omicron is therefore much less sensitive to the anti-SARS-CoV-2 antibodies currently used in clinical practice or obtained after two vaccine doses.
-----
The scientists began by testing nine monoclonal antibodies used in clinical practice or currently in preclinical development. Six antibodies lost all antiviral activity, and the other three were 3 to 80 times less effective against Omicron than against Delta. The antibodies Bamlanivimab/Etesevimab (a combination developed by Lilly), Casirivimab/Imdevimab (a combination developed by Roche and known as Ronapreve) and Regdanvimab (developed by Celtrion) no longer had any antiviral effect against Omicron. The Tixagevimab/Cilgavimab combination (developed by AstraZeneca under the name Evusheld) was 80 times less effective against Omicron than against Delta.
-----
No comments:
Post a Comment